Ceridian HCM (CDAY) Tops Q2 EPS by 11c; Offers FY22 Revenue Guidance

Ceridian HCM (NYSE: CDAY) reported Q2 EPS of $0.21, $0.11 better than the analyst estimate of $0.10. Revenue for the quarter came in at $301.2 million versus the consensus estimate of $294.53 million.

GUIDANCE:

Ceridian HCM sees FY2022 revenue of $1.218-1.233 billion.

For earnings history and earnings-related data on Ceridian HCM (CDAY) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• ResMed (RMD) Tops Q3 EPS by 20c
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance